An integrated quantitative systems pharmacology virtual population approach for calibration with oncology efficacy endpoints
CPT: Pharmacometrics & Systems Pharmacology · 2025
DOI: 10.1002/psp4.13270 ↗Kurz gefasst
Fachartikel in der Zeitschrift CPT: Pharmacometrics & Systems Pharmacology, 2025. Verfasst von Nathan Braniff und 8 weiteren Autor:innen. Beteiligte Einrichtung: Pharmacometrics & Systems Pharmacology, Pfizer Inc., La Jolla, California, USA. Hauptthemen laut MEDLINE: Neoplasms, Antineoplastic Agents, Network Pharmacology. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
In drug development, quantitative systems pharmacology (QSP) models are becoming an increasingly important mathematical tool for understanding response variability and for generating predictions to inform development decisions. Virtual populations are essential for sampling uncertainty and potential variability in QSP model predictions, but many clinical efficacy endpoints can be difficult to capture with QSP models that typically rely on mechanistic biomarkers. In oncology, challenges are particularly significant when connecting tumor size with time‐to‐event endpoints like progression‐free survival while also accounting for censoring due to consent withdrawal, loss in follow‐up, or safety criteria. Here, we expand on our prior work and propose an extended virtual population selection algorithm that can jointly match tumor burden dynamics and progression‐free survival times in the presence of censoring. We illustrate the core components of our algorithm through simulation and calibration of a signaling pathway model that was fitted to clinical data for a small molecule targeted inhibitor. This methodology provides an approach that can be tailored to other virtual population simulations aiming to match survival endpoints for solid‐tumor clinical datasets.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Pharmacometrics & Systems Pharmacology, Pfizer Inc., La Jolla, California, USA.
- Vantage Research Inc., Lewes, Delaware, USA.
- Pharmacometrics & Systems Pharmacology, Pfizer Inc., Cambridge, Massachusetts, USA.
ORCID-Profile: Tanvi Joshi, Kamrine Poels, Cynthia J Musante
Zitieren
APA
Braniff, N., Joshi, T., Cassidy, T., Trogdon, M., Kumar, R., Poels, K., Allen, R., Musante, C. J., & Shtylla, B. (2025). An integrated quantitative systems pharmacology virtual population approach for calibration with oncology efficacy endpoints. CPT: Pharmacometrics & Systems Pharmacology. https://doi.org/10.1002/psp4.13270
Vancouver
Braniff N, Joshi T, Cassidy T, Trogdon M, Kumar R, Poels K, et al. An integrated quantitative systems pharmacology virtual population approach for calibration with oncology efficacy endpoints. CPT: Pharmacometrics & Systems Pharmacology. 2025. doi:10.1002/psp4.13270
BibTeX
@article{Braniff2025,
author = {Braniff, Nathan and Joshi, Tanvi and Cassidy, Tyler and Trogdon, Michael and Kumar, Rukmini and Poels, Kamrine and Allen, Richard and Musante, Cynthia J and Shtylla, Blerta},
title = {An integrated quantitative systems pharmacology virtual population approach for calibration with oncology efficacy endpoints},
journal = {CPT: Pharmacometrics & Systems Pharmacology},
year = {2025},
doi = {10.1002/psp4.13270}
}
EUVIMED